Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 193,674,288
  • Shares Outstanding, K 2,524,101
  • Annual Sales, $ 46,840 M
  • Annual Income, $ 9,843 M
  • 60-Month Beta 0.48
  • Price/Sales 4.13
  • Price/Cash Flow 11.46
  • Price/Book 7.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 1.12
  • Number of Estimates 4
  • High Estimate 1.24
  • Low Estimate 1.01
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -13.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.57 +4.29%
on 06/15/20
81.66 -6.04%
on 06/11/20
-5.04 (-6.16%)
since 06/10/20
3-Month
73.57 +4.29%
on 06/15/20
84.67 -9.38%
on 04/27/20
-5.76 (-6.98%)
since 04/09/20
52-Week
65.25 +17.59%
on 03/23/20
92.64 -17.17%
on 12/20/19
-8.09 (-9.54%)
since 07/10/19

Most Recent Stories

More News
'A slap in the face:' Goya faces boycott over Trump praise

NEW YORK (AP) — The CEO of food company Goya is facing an uproar over his praise for President Donald Trump, with some Latino families purging their pantries of the products and scrambling to find alternatives...

MRK : 76.73 (+0.05%)
Cancer Cachexia Market to Reach USD 2.93 Billion by 2027; Rapid Inclination towards Combination Therapies to Aid Growth: Fortune Business Insights(TM)

The global cancer cachexia market is anticipated to gain traction from the rising shift of the healthcare providers towards combination therapies. Such therapies are aiding in improving the lean body mass...

ABBV : 96.83 (-1.13%)
ANIP : 27.23 (+3.22%)
HKMPF : 27.5000 (-0.18%)
MRK : 76.73 (+0.05%)
PFE : 33.83 (+1.11%)
TEVA : 11.76 (+1.29%)
Merck's Keytruda Gets Priority Review for Lymphoma Indication

FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.

PFE : 33.83 (+1.11%)
MRK : 76.73 (+0.05%)
GSK : 39.91 (-1.14%)
SGEN : 174.35 (-3.76%)
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal

Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs

AZN : 53.76 (-0.39%)
RHHBY : 44.2300 (-0.61%)
PFE : 33.83 (+1.11%)
MRK : 76.73 (+0.05%)
LLY : 163.36 (-1.86%)
GSK : 39.91 (-1.14%)
ABBV : 96.83 (-1.13%)
Ammonium Sulfate Market Expected to Expand at a CAGR of 3% during 2018-2026|Sumitomo Chemical Co. Ltd., Nutrien Ltd.

Research Nester has released a report titled which also includes some of the prominent market analyzing parameters such as industry growth drivers, restraints, supply and demand risk, market attractiveness,...

LNXSF : 54.0945 (+0.65%)
MKKGY : 24.8800 (-0.49%)
NTR.TO : 43.16 (+1.55%)
SOMMF : 2.7700 (-2.81%)
NTR : 31.76 (+1.60%)
EVK : 1.1900 (+8.18%)
MRK : 76.73 (+0.05%)
DSM : 7.51 (+0.67%)
HON : 142.45 (+0.76%)
BAS : 0.44 (-5.23%)
Merck Opens its Largest M Lab(TM) Collaboration Center in Shanghai

-- Focus on improving and optimizing drug discovery, development and manufacturing

MRK : 76.73 (+0.05%)
MilliporeSigma Opens its Largest M Lab(EQNX::trademark) Collaboration Center in Shanghai

MilliporeSigma Opens its Largest M Lab(EQNX::trademark) Collaboration Center in Shanghai

MRK : 76.73 (+0.05%)
MKKGY : 24.8800 (-0.49%)
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO(R) (fluralaner) Monthly Chews

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA, [NYSE: MRK], today announced the U.S. Food and Drug Administration's...

MRK : 76.73 (+0.05%)
/R E P E A T -- Announcement of the winners of the Innove-Onco Competition/

/R E P E A T -- Announcement of the winners of the Innove-Onco Competition/

GSK : 39.91 (-1.14%)
MRK : 76.73 (+0.05%)
Bacterial Conjunctivitis Drugs Market Size Study with COVID-19 Impact 2020, Share, Industry Analysis, Growth, Trends, Sales Revenue, Segmentation and Forecast to 2026

AKRX : 0.0900 (-51.01%)
AGN : 193.02 (+0.02%)
BAYRY : 17.9800 (+0.45%)
MRK : 76.73 (+0.05%)
NVS : 87.01 (-0.38%)
PRGO : 55.17 (+1.68%)
PFE : 33.83 (+1.11%)
SNPHF : 17.7000 (-4.84%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 77.78
1st Resistance Point 77.25
Last Price 76.73
1st Support Level 76.30
2nd Support Level 75.88

See More

52-Week High 92.64
Fibonacci 61.8% 82.18
Fibonacci 50% 78.94
Last Price 76.73
Fibonacci 38.2% 75.71
52-Week Low 65.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar